Key result
The OACIS-LIPID study is a randomized trial designed to evaluate whether early use of pravastatin prevents secondary cardiac events in 350 patients with AMI and hyperlipidemia.
Why the study?
Does early use of pravastatin 10 mg per day prevent secondary cardiac events in Japanese patients with acute myocardial infarction and mild to moderate hyperlipidemia?
RCT (n=350)
Open-label
Does early use of pravastatin 10 mg per day prevent secondary cardiac events in Japanese patients with acute myocardial infarction and mild to moderate hyperlipidemia?
This paper describes the rationale and design of the OACIS-LIPID study, which evaluates the efficacy of early, standard-dose pravastatin (10 mg/day) for secondary prevention in Japanese patients following an acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
OACIS-LIPID RCT will test early pravastatin 10 mg/day for secondary prevention post-AMI in Japanese patients; addresses evidence gap in Asian populations.
We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.
No takes yet. Share an insight, caveat, or question.
Sakata et al. (2005) conducted an RCT in Acute myocardial infarction and hyperlipidemia (n=350). Pravastatin vs. No pravastatin (dietary counseling only) was evaluated on Combination of death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke. The OACIS-LIPID study is a randomized trial designed to evaluate whether early use of pravastatin prevents secondary cardiac events in 350 patients with AMI and hyperlipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: